Carl Morrison

MD, DVM
Anatomic Pathology

Specializing In:

Molecular Pathology

Special Interests:

Genomic analysis of tumors

About Carl Morrison

Biography:

Dr. Carl D. Morrison joined the faculty of Roswell Park Comprehensive Cancer Center in January 2007, and is currently the Chair of the Department of Pathology & Laboratory Medicine, Senior Vice President of Scientific Development and Integrative Medicine, and Professor of Oncology. Prior to coming to Roswell Park, Dr. Morrison spent five years as faculty at The Ohio State University Medical Center after completing his residency there in Anatomic Pathology. Dr. Morrison is a board-certified pathologist with a Certificate of Qualification in Oncology in NYS who has an interest in both clinical and research areas.

As Senior Vice President of Scientific Development and Integrative Medicine, Dr. Morrison supports the development of new core capabilities and technology platforms in order to conduct highly integrative research across both the basic sciences and clinical care. As Chair of the Department of Pathology Dr Morrison leads our clinical laboratories that provide an essential component of patient care.

Positions

Roswell Park Comprehensive Cancer Center

  • Senior Vice President, Scientific Development and Integrative Medicine
  • Professor of Oncology
  • Chair, Department of Pathology & Laboratory Medicine

Background

Education and Training:

  • MD - University of Kentucky College of Medicine, Lexington, KY
  • DVM - Ohio State University, Columbus, OH

Residency:

  • Anatomic Pathology, Ohio State University, Columbus, OH

Fellowship:

  • Cytopathology, Ohio State University, Columbus, OH

Board Certification:

  • Anatomic Pathology, American Board of Pathology
  • NYS Certificate of Qualification in Oncology Molecular

Professional Memberships:

  • College of American Pathologist (CAP)
  • United States and Canadian Academy of Pathologists (USCAP)
  • American Society of Clinical Oncology (ASCO)

Professional Experience:

  • Previous Member, CMS PAMA Federal Advisory Committee
  • Previous Member, Molecular Oncology Committee, College of American Pathologists
  • Founding Member, Department of Defense (DOD) Lung Integration Panel
  • Previous Member, External Advisory Board Member, DOD Lung Cancer Biospecimen Resource Network
  • Previous President, CMO, Board Chair, Omniseq Inc
  • Previous Director Pathology Resource Network Roswell Park Cancer Institute
  • Previous Director Clinical Data Network Roswell Park Cancer Institute

Honors & Awards:

  • Tomasi Hope Award

Research

Research Overview:

Dr. Morrison has more than 150 publications regarding molecular technology in a translational setting that are examples of his understanding of the needs of cutting-edge technologies in both a research and clinical setting. The productivity and impact of Dr. Morrison’s published work is consistent with an h-index of 28, which is based on the set of the author’s most cited papers and the number of citations that they have received in other publications. Through his research efforts Dr. Morrison has participated as PI or Co-PI for more than 40 grants, many of which were or are funded by the NCI. Complementing Dr. Morrison’s research interests is his clinical involvement in molecular and surgical pathology. In his role in molecular pathology he designs, validates and signs out molecular pathology tests that impact patient care on a daily basis. As a surgical pathologist with expertise in bone and soft tissue pathology he is an essential part of the diagnostic process that defines patient care


Featured on Cancer Talk


Publications

Full Publications list on PubMed

1: Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. Identification of targets for prostate cancer immunotherapy. Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6. PubMed PMID: 30614027.

2: Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. PubMed PMID: 30709424; PubMed Central PMCID: PMC6359802.

3: Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5. PubMed PMID: 30678715; PubMed Central PMCID: PMC6346512.

4: Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x. PubMed PMID: 30658646; PubMed Central PMCID: PMC6339275.

5: George S, Papanicolau-Sengos A, Lenzo FL, Conroy JM, Nesline M, Pabla S, Glenn ST, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Galluzzi L, Morrison C. PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. Oncoimmunology. 2018 May 29;7(12):e1460298. doi: 10.1080/2162402X.2018.1460298. eCollection 2018. PubMed PMID: 30524881; PubMed Central PMCID: PMC6279415.

6: Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8. PubMed PMID: 29743104; PubMed Central PMCID: PMC5944039.

7: Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, Andreas J, Giamo V, Lenzo FL, Hyland FCL, Omilian A, Bshara W, Qin M, He J, Puzanov I, Ernstoff MS, Gardner M, Galluzzi L, Morrison C. Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. J Mol Diagn. 2018 Jan;20(1):95-109. doi: 10.1016/j.jmoldx.2017.10.001. Epub 2017 Oct 20. PubMed PMID: 29061374.


8: Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget. 2017 Jan 10;8(2):3197-3205. doi: 10.18632/oncotarget.13691. PubMed PMID: 27911273; PubMed Central PMCID: PMC5356875.